Clinical Trials Logo

Clinical Trial Summary

Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.


Clinical Trial Description

Digestive cancers account for 30% of all cancers. The most common of these colorectal cancer (CRC) is the third most common cause of cancer in the world. In the metastatic phase, patients with digestive cancers generally benefit from medical treatment based on cytotoxic chemotherapy, which can be combined with targeted therapy in certain locations. Their use is based on demonstrating a significant improvement in the overall survival of patients. However, the therapeutic choice and follow-up of these treatments as a the first line treatment and beyond remain difficult given a cruel lack of biomarkers capable of predicting the response to these different molecules upstream but also usable during treatment to evaluate their efficacy or identify the development of secondary resistance mechanisms. Indeed, the only biomarkers currently validated and used before the initiation of anti-cancer treatment to stratify patients are: - the search for mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma rat sarcoma viral oncogene (NRAS) oncogenes as predictive factors for non-response to anti-Epidermal Growth Factor receptor (EGFR) in colorectal adenocarcinomas. - the search for overexpression of the human epidermal growth factor (HER2) receptor to introduce trastuzumab treatment in esophageal adenocarcinomas. In addition, they are conventionally determined from tumor tissue, which requires an invasive biopsy or surgical sampling that is difficult to repeat over time. In this context, it seems essential to us to identify new parameters allowing a better personalization of anti-cancer treatments, by favouring blood biomarkers that have the advantage of being evaluated in a minimally invasive manner and therefore be repeated to be able to judge tumor dynamics. To this end, we propose the creation of a collection of samples that will be collected before and then under treatment in patients with digestive adenocarcinoma in the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03978078
Study type Interventional
Source Institut du Cancer de Montpellier - Val d'Aurelle
Contact Jean-Pierre Bleuse, MD
Phone 4 67 61 31 02
Email jean-pierre.bleuse@icm.unicancer.fr
Status Recruiting
Phase N/A
Start date September 12, 2016
Completion date April 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04500990 - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Terminated NCT03724071 - Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. Phase 1/Phase 2
Terminated NCT02602067 - 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Phase 1
Completed NCT05374369 - Retrospective Analysis of Colorectal Cancer Screening Results
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT04456140 - Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study Phase 1
Completed NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT06223230 - Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors N/A
Withdrawn NCT04811833 - Gastrointestinal Anastomosis Using MonoPlus® Suture
Terminated NCT05160168 - A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Phase 1/Phase 2
Completed NCT04722055 - A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
Recruiting NCT05238584 - Total Versus Partial Omentectomy in the Treatment of Gastric Cancer N/A
Recruiting NCT04084249 - ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial N/A
Terminated NCT01939210 - Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy N/A
Recruiting NCT05980416 - Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 Phase 1
Recruiting NCT04929015 - Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study) N/A
Recruiting NCT04493632 - OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
Recruiting NCT04133324 - C-protein Reactive for the Detection of Anastomotic Leakage After Surgery for Digestive Cancer